Johnson & Johnson will invest $2 billion in North Carolina to expand U.S. manufacturing capacity amid proposed import duties on drugs. The company reached a 10-year agreement with Fujifilm Diosynth for a more than 160,000-square-foot Holly Springs facility, projected to create about 120 jobs. Fujifilm previously signed a more than $3 billion, 10-year deal with Regeneron to manufacture and supply drug products at the North Carolina site. J&J plans additional U.S. facilities and expansions in coming months and increased planned U.S. investments by 25% to more than $55 billion over four years, including a separate plant in Wilson, North Carolina. Major drugmakers are also expanding U.S. footprints in response to tariff threats.
Johnson & Johnson said on Thursday it would invest $2 billion in North Carolina as it aims to expand its U.S. manufacturing presence amid looming drug import duties proposed by President Donald Trump's administration. Major drugmakers, including Eli Lilly and AstraZeneca, have also committed to shell out billions of dollars to scale up their U.S. footprint in response to Trump's efforts, including tariff threats.
J&J said on Thursday it has reached a 10-year agreement with Tokyo-based contract drug developer Fujifilm Diosynth for its more than 160,000-square-foot manufacturing facility in Holly Springs, North Carolina, which would create about 120 new jobs. Fujifilm in April had signed a more than $3 billion deal with Regeneron to manufacture and supply drug products for the U.S.-based company at its North Carolina facility for a span of 10 years.
Collection
[
|
...
]